| Name | Title | Contact Details |
|---|
SOC Telemed (SOC) is the largest national provider of telemedicine technology and solutions to hospitals, health systems, post-acute providers, physician networks, value-based care organizations, and health plans. Built on proven and scalable infrastructure as an enterprise-wide solution, SOC`s technology platform, Telemed IQ, rapidly deploys and seamlessly optimizes telemedicine programs across the continuum of care. SOC provides a supportive and dedicated partner presence, virtually delivering patient care through teleNeurology, telePsychiatry and teleICU as well as enabling healthcare organizations to build sustainable telemedicine programs in any clinical specialty. SOC enables organizations to enrich their care models and touch more lives by supplying healthcare teams with industry-leading solutions that drive improved clinical care, patient outcomes, and organizational health. The company was the first provider of acute clinical telemedicine services to earn The Joint Commission`s Gold Seal of Approval and has maintained that accreditation every year since inception.
Harlan County Health System is a Alma, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cirrus Health is an organization uniquely qualified to successfully adapt to the ever-changing healthcare environment. While the complexity of today's healthcare creates barriers for some companies, it is a market of opportunities for Cirrus Health.
Health Management Associates is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Lansing, MI. To find more information about Health Management Associates, please visit www.healthmanagement.com
HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer. The Company may also explore acquiring or licensing innovative therapeutics addressing unmet needs and orphan indications beyond cancer. We are focused on the development of therapies for more than one type of cancer, with initial emphasis in the U.S. market, based upon repurposing the currently marketed antifungal drug itraconazole for new indications in oncology.